These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 32772775

  • 1. Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy.
    Cao Z, Meng S, Zheng Y, Wang J, Wang R, Chen X.
    Innate Immun; 2020 Oct; 26(7):601-608. PubMed ID: 32772775
    [Abstract] [Full Text] [Related]

  • 2. Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study.
    Wen C, Wang Y, Tian H, Lei Y, Wang Z, Cai D, Zhou Z, Shi X.
    Front Cell Infect Microbiol; 2023 Oct; 13():1332232. PubMed ID: 38292859
    [Abstract] [Full Text] [Related]

  • 3. B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy.
    Cao Z, Meng S, Zheng Y, Wang J, Wang R, Chen X.
    PLoS One; 2020 Oct; 15(12):e0242559. PubMed ID: 33264330
    [Abstract] [Full Text] [Related]

  • 4. Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion.
    Bruder Costa J, Dufeu-Duchesne T, Leroy V, Bertucci I, Bouvier-Alias M, Pouget N, Brevot-Lutton O, Bourliere M, Zoulim F, Plumas J, Aspord C, ANRS HB06 PEGAN study group.
    PLoS One; 2016 Oct; 11(6):e0158297. PubMed ID: 27348813
    [Abstract] [Full Text] [Related]

  • 5. Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir.
    Stelma F, de Niet A, Tempelmans Plat-Sinnige MJ, Jansen L, Takkenberg RB, Reesink HW, Kootstra NA, van Leeuwen EM.
    J Infect Dis; 2015 Oct 01; 212(7):1042-51. PubMed ID: 25791117
    [Abstract] [Full Text] [Related]

  • 6. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study.
    Wu FP, Yang Y, Li M, Liu YX, Li YP, Wang WJ, Shi JJ, Zhang X, Jia XL, Dang SS.
    World J Gastroenterol; 2020 Apr 07; 26(13):1525-1539. PubMed ID: 32308352
    [Abstract] [Full Text] [Related]

  • 7. Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB.
    Yan W, Wu D, Wang X, Chen T, Lai Q, Zheng Q, Jiang J, Hou J, Han M, Ning Q.
    Antivir Ther; 2015 Apr 07; 20(6):591-602. PubMed ID: 25814467
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ, Yu YQ, Chen SL, Fan P, Shao LY, Chen JZ, Li CS, Yi B, Chen WC, Xie SY, Mao XN, Zou HH, Zhang WH.
    Antimicrob Agents Chemother; 2015 Jul 07; 59(7):4121-8. PubMed ID: 25941216
    [Abstract] [Full Text] [Related]

  • 10. Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis.
    Song A, Lin X, Lu J, Ren S, Cao Z, Zheng S, Hu Z, Li H, Shen C, Chen X.
    Front Immunol; 2021 Jul 07; 12():779347. PubMed ID: 34804072
    [Abstract] [Full Text] [Related]

  • 11. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha.
    Cao Z, Liu Y, Ma L, Lu J, Jin Y, Ren S, He Z, Shen C, Chen X.
    Hepatology; 2017 Oct 07; 66(4):1058-1066. PubMed ID: 28407271
    [Abstract] [Full Text] [Related]

  • 12. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL.
    PLoS One; 2015 Oct 07; 10(4):e0122259. PubMed ID: 25835020
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. CD56bright natural killer cells induce HBsAg reduction via cytolysis and cccDNA decay in long-term entecavir-treated patients switching to peginterferon alfa-2a.
    Shi A, Zhang X, Xiao F, Zhu L, Yan W, Han M, Luo X, Chen T, Ning Q.
    J Viral Hepat; 2018 Nov 07; 25(11):1352-1362. PubMed ID: 29888839
    [Abstract] [Full Text] [Related]

  • 17. [HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study].
    Hu P, Shang J, Zhang WH, Gong GZ, Li YG, Chen XY, Jiang JN, Xie Q, Dou XG, Sun YT, Li YF, Liu YX, Liu GZ, Ma DW, Chi XL, Tang H, Li XO, Xie Y, Chen XP, Jiang JJ, Zha P, Hou JL, Gao ZL, Fan HM, Ding JG, Zhang DZ, Ren H.
    Zhonghua Gan Zang Bing Za Zhi; 2018 Oct 20; 26(10):756-764. PubMed ID: 30481882
    [Abstract] [Full Text] [Related]

  • 18. Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment.
    Li MH, Zhang L, Qu XJ, Lu Y, Shen G, Wu SL, Chang M, Liu RY, Hu LP, Li ZZ, Hua WH, Song SJ, Xie Y.
    Chin Med J (Engl); 2017 Mar 05; 130(5):559-565. PubMed ID: 28229987
    [Abstract] [Full Text] [Related]

  • 19. Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.
    Wang Z, Li X, Shi C, Zhang M, Chen R, Wu W, Hou Q, Ke W, Fan T, Wen Z, Hao X, Qu N.
    Mol Med Rep; 2015 Jan 05; 11(1):427-33. PubMed ID: 25324041
    [Abstract] [Full Text] [Related]

  • 20. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
    Ouzan D, Pénaranda G, Joly H, Khiri H, Pironti A, Halfon P.
    J Clin Virol; 2013 Dec 05; 58(4):713-7. PubMed ID: 24183313
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.